• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Considerations When Switching Therapy

Video

A variety of immunotherapeutic agents with differing mechanisms of action are now available for the treatment of cancer. Richard W. Joseph, MD, discusses considerations regarding switching therapy in patients who experience disease progression.

While studies have been conducted of patients placed on an anti-PD-1 therapy following disease progression on ipilimumab, Dr Joseph remarks, there is a lack of data regarding treating patients with ipilimumab following disease progression on anti-PD-1 therapy.

Among other factors, treatment toxicities need to be considered before switching therapy, he adds. “In my personal experience, I tend to see that some of the side effects that patients had from ipilimumab will be reaggravated with anti-PD-1 [therapy]. I have also seen that not happen as well,” he comments.

Dr Joseph also briefly discusses the use of combination therapy (ipilimumab and anti-PD-1 therapy), and describes how the tolerability of combination therapy further complicates the making of treatment decisions.


Related Videos
Jaime Almandoz, MD, MBA
Martin Edelman, MD
Benjamin Chen, MD, PhD
4 experts are featured in this series.
1 expert is featured in this series.
4 experts are featured in this series.
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
4 experts are featured in this series.
5 experts are featured in this series
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.